ARCHIVES

In Brief: VP-16 NDA Approved By FDA Only For Refractory Testicular Cancer; Removed From Group C List

This article is from The Cancer Letter archive.

Vol. 09 No. 46 | December 2, 1983

Download PDF Visit The Full Archive

Related Articles

NCI funds 17 EDRN biomarker labs. Bush signs omnibus funding legislation.

December 10, 2004

CCOP Letters Of Intent Reach 232; Frelick Experts 80-90 Percent Of them To Qualify For Applications

September 3, 1982

In Brief: Judge Rules FDA Modernization Act Violates First Amendment Over Publications Policy

August 6, 1999

Eight Practicing Physicians On Board are Enough, Need Some Scientists Now, DeVita Says

December 9, 1983

Immune Therapy Possible For Metastatic Breast Cancer

September 24, 2004

NCI Pulls Back Curtain on “Zone of Uncertainty” — Funding Patterns Released With Little Comment

May 4, 2012